CD96 as a Potential Immune Regulator in Cancers

The discovery of CTLA-4 and PD-1 checkpoints has prompted scientific researchers and the pharmaceutical industry to develop and conduct extensive research on tumor-specific inhibitors. As a result, the list of potential immune checkpoint molecules is growing over time. Receptors for nectin and necti...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Shikai, Isayev, Orkhan, Werner, Jens, Bazhin, Alexandr V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866520/
https://www.ncbi.nlm.nih.gov/pubmed/36674817
http://dx.doi.org/10.3390/ijms24021303
_version_ 1784876112449372160
author Feng, Shikai
Isayev, Orkhan
Werner, Jens
Bazhin, Alexandr V.
author_facet Feng, Shikai
Isayev, Orkhan
Werner, Jens
Bazhin, Alexandr V.
author_sort Feng, Shikai
collection PubMed
description The discovery of CTLA-4 and PD-1 checkpoints has prompted scientific researchers and the pharmaceutical industry to develop and conduct extensive research on tumor-specific inhibitors. As a result, the list of potential immune checkpoint molecules is growing over time. Receptors for nectin and nectin-like proteins have recently emerged as promising targets for cancer immunotherapy. Potential immune checkpoints, including CD226, TIGIT, and CD96, belong to this receptor class. Among them, CD96 has received little attention. In this mini-review, we aim to discuss the basic biology of CD96 as well as the most recent relevant research on this as a promising candidate for cancer immunotherapy.
format Online
Article
Text
id pubmed-9866520
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98665202023-01-22 CD96 as a Potential Immune Regulator in Cancers Feng, Shikai Isayev, Orkhan Werner, Jens Bazhin, Alexandr V. Int J Mol Sci Review The discovery of CTLA-4 and PD-1 checkpoints has prompted scientific researchers and the pharmaceutical industry to develop and conduct extensive research on tumor-specific inhibitors. As a result, the list of potential immune checkpoint molecules is growing over time. Receptors for nectin and nectin-like proteins have recently emerged as promising targets for cancer immunotherapy. Potential immune checkpoints, including CD226, TIGIT, and CD96, belong to this receptor class. Among them, CD96 has received little attention. In this mini-review, we aim to discuss the basic biology of CD96 as well as the most recent relevant research on this as a promising candidate for cancer immunotherapy. MDPI 2023-01-09 /pmc/articles/PMC9866520/ /pubmed/36674817 http://dx.doi.org/10.3390/ijms24021303 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Feng, Shikai
Isayev, Orkhan
Werner, Jens
Bazhin, Alexandr V.
CD96 as a Potential Immune Regulator in Cancers
title CD96 as a Potential Immune Regulator in Cancers
title_full CD96 as a Potential Immune Regulator in Cancers
title_fullStr CD96 as a Potential Immune Regulator in Cancers
title_full_unstemmed CD96 as a Potential Immune Regulator in Cancers
title_short CD96 as a Potential Immune Regulator in Cancers
title_sort cd96 as a potential immune regulator in cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866520/
https://www.ncbi.nlm.nih.gov/pubmed/36674817
http://dx.doi.org/10.3390/ijms24021303
work_keys_str_mv AT fengshikai cd96asapotentialimmuneregulatorincancers
AT isayevorkhan cd96asapotentialimmuneregulatorincancers
AT wernerjens cd96asapotentialimmuneregulatorincancers
AT bazhinalexandrv cd96asapotentialimmuneregulatorincancers

Ejemplares similares